lamotrigine has been researched along with Chronic Disease in 30 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the analgesic efficacy of lamotrigine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse effects reported in the studies." | 8.89 | Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Wiffen, PJ, 2013) |
| "To assess analgesic efficacy and adverse effects of the antiepileptic drug lamotrigine in acute and chronic pain." | 8.87 | Lamotrigine for acute and chronic pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2011) |
| "To assess the analgesic efficacy and adverse effects of the anticonvulsant lamotrigine for acute and chronic pain." | 8.84 | Lamotrigine for acute and chronic pain. ( Rees, J; Wiffen, PJ, 2007) |
| " We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models." | 7.79 | Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. ( Bähr, M; Hein, K; Könnecke, B; Levkovitch-Verbin, H; Ofri, R; Sandalon, S; Sättler, MB; Simons, M, 2013) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 7.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "Patients with generalized epilepsy (p = 0." | 5.31 | A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. ( Lhatoo, SD; Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "The anticonvulsant lamotrigine has been reported to be efficacious and well tolerated as monotherapy in the treatment of bipolar patients as well as in treatment-refractory bipolar disorder." | 5.10 | Lamotrigine as an augmentation agent in treatment-resistant depression. ( Barbee, JG; Jamhour, NJ, 2002) |
| "To assess the analgesic efficacy of lamotrigine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse effects reported in the studies." | 4.89 | Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Wiffen, PJ, 2013) |
| "To assess analgesic efficacy and adverse effects of the antiepileptic drug lamotrigine in acute and chronic pain." | 4.87 | Lamotrigine for acute and chronic pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2011) |
| "To assess the analgesic efficacy and adverse effects of the anticonvulsant lamotrigine for acute and chronic pain." | 4.84 | Lamotrigine for acute and chronic pain. ( Rees, J; Wiffen, PJ, 2007) |
| " We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models." | 3.79 | Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. ( Bähr, M; Hein, K; Könnecke, B; Levkovitch-Verbin, H; Ofri, R; Sandalon, S; Sättler, MB; Simons, M, 2013) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 3.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| "The TACs include cluster headache, paroxysmal hemicrania, and short-lasting neuralgiform headache attacks with conjunctival injection and tearing; hemicrania continua, although classified separately by the International Headache Society, shares many features of both migraine and the TACs." | 2.49 | Primary headache disorders. ( Benoliel, R; Eliav, E, 2013) |
| "Tinnitus is the perception of sound or noise in the absence of an external or internal acoustic stimulation." | 2.47 | Anticonvulsants for tinnitus. ( Hoekstra, CE; Rovers, MM; Rynja, SP; van Zanten, GA, 2011) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "The treatment with lamotrigine increased the superoxide dismutase (SOD) and catalase activity (CAT) activities in the amygdala of stressed rats." | 1.39 | Effects of lamotrigine on behavior, oxidative parameters and signaling cascades in rats exposed to the chronic mild stress model. ( Abelaira, HM; Dal-Pizzol, F; Mina, F; Quevedo, J; Réus, GZ; Ribeiro, KF; Romano-Silva, MA; Rosa, DV; Santana, CV; Steckert, AV, 2013) |
| "Lamotrigine is a novel anticonvulsant initially used in epilepsy treatment." | 1.33 | The relevance of monitoring lamotrigine serum concentrations in chronic pain patients. ( Devulder, J, 2006) |
| "Patients with generalized epilepsy (p = 0." | 1.31 | A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. ( Lhatoo, SD; Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "Gabapentin was effective in approximately 50% of pretreated patients with intractable pain." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Wahab, AF | 1 |
| Afify, MA | 1 |
| Mahfouz, AM | 1 |
| Shahzad, N | 1 |
| Bamagous, GA | 1 |
| Al Ghamdi, SS | 1 |
| Abelaira, HM | 1 |
| Réus, GZ | 1 |
| Ribeiro, KF | 1 |
| Steckert, AV | 1 |
| Mina, F | 1 |
| Rosa, DV | 1 |
| Santana, CV | 1 |
| Romano-Silva, MA | 1 |
| Dal-Pizzol, F | 1 |
| Quevedo, J | 1 |
| Benoliel, R | 1 |
| Eliav, E | 1 |
| Sandalon, S | 1 |
| Könnecke, B | 1 |
| Levkovitch-Verbin, H | 1 |
| Simons, M | 1 |
| Hein, K | 1 |
| Sättler, MB | 1 |
| Bähr, M | 1 |
| Ofri, R | 1 |
| Wiffen, PJ | 3 |
| Derry, S | 2 |
| Moore, RA | 2 |
| Chen, J | 1 |
| Quan, QY | 1 |
| Yang, F | 1 |
| Wang, Y | 1 |
| Wang, JC | 1 |
| Zhao, G | 1 |
| Jiang, W | 1 |
| Hoekstra, CE | 1 |
| Rynja, SP | 1 |
| van Zanten, GA | 1 |
| Rovers, MM | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Barbee, JG | 1 |
| Jamhour, NJ | 1 |
| Goforth, HW | 1 |
| Rao, M | 1 |
| Sucholeiki, R | 1 |
| Baldassano, CF | 1 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Yatham, LN | 1 |
| Kennedy, SH | 1 |
| O'Donovan, C | 1 |
| Parikh, S | 1 |
| MacQueen, G | 1 |
| McIntyre, R | 1 |
| Sharma, V | 1 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 1 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Devulder, J | 2 |
| Rees, J | 1 |
| van Doorn, PA | 1 |
| Pavlovic, ZM | 1 |
| Bras, M | 1 |
| Bakunts, GO | 1 |
| Burd, GS | 1 |
| Vaĭntrub, MIa | 1 |
| Karlov, VA | 1 |
| Savchenko, IuN | 1 |
| Solovykh, NN | 2 |
| Shershever, AS | 1 |
| Shprakh, VV | 1 |
| Korotkov, AG | 1 |
| Nakamura-Craig, M | 1 |
| Follenfant, RL | 1 |
| Walker, MC | 1 |
| Li, LM | 1 |
| Sander, JW | 4 |
| Hunter, JC | 1 |
| Gogas, KR | 1 |
| Hedley, LR | 1 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Wong, IC | 3 |
| Chadwick, DW | 1 |
| Fenwick, PB | 1 |
| Mawer, GE | 2 |
| De Laat, M | 1 |
| Lhatoo, SD | 2 |
| Polizzi, G | 1 |
| Sierra, M | 1 |
| Phillips, ML | 1 |
| Lambert, MV | 1 |
| Senior, C | 1 |
| David, AS | 1 |
| Krystal, JH | 1 |
| Gustorff, B | 1 |
| Nahlik, G | 1 |
| Spacek, A | 1 |
| Kress, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression[NCT00652171] | Phase 3 | 34 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
9 reviews available for lamotrigine and Chronic Disease
| Article | Year |
|---|---|
Primary headache disorders.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anticonvulsants; Chronic Disease; Cluster Headache; Cycloox | 2013 |
Lamotrigine for chronic neuropathic pain and fibromyalgia in adults.
Topics: Acute Disease; Adult; Analgesics; Anticonvulsants; Chronic Disease; Fibromyalgia; Humans; Lamotrigin | 2013 |
Lamotrigine for acute and chronic pain.
Topics: Acute Disease; Analgesics; Chronic Disease; Humans; Lamotrigine; Pain; Randomized Controlled Trials | 2011 |
Anticonvulsants for tinnitus.
Topics: Administration, Oral; Amines; Anticonvulsants; Carbamazepine; Chronic Disease; Cyclohexanecarboxylic | 2011 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Lamotrigine for acute and chronic pain.
Topics: Acute Disease; Analgesics; Anticonvulsants; Chronic Disease; Humans; Lamotrigine; Pain; Randomized C | 2007 |
[Guideline on polyneuropathy].
Topics: Amitriptyline; Analgesics, Non-Narcotic; Carbamazepine; Chronic Disease; Diabetes Complications; Ele | 2007 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
2 trials available for lamotrigine and Chronic Disease
| Article | Year |
|---|---|
Lamotrigine as an augmentation agent in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Chronic Disease | 2002 |
[Lamiktal in the treatment of epilepsy patients].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chronic Disease; Epilepsies, Partial; E | 1995 |
19 other studies available for lamotrigine and Chronic Disease
| Article | Year |
|---|---|
Vitamin D enhances antiepileptic and cognitive effects of lamotrigine in pentylenetetrazole-kindled rats.
Topics: Animals; Anticonvulsants; Antioxidants; Cholecalciferol; Chronic Disease; Cognition; Disease Models, | 2017 |
Effects of lamotrigine on behavior, oxidative parameters and signaling cascades in rats exposed to the chronic mild stress model.
Topics: Amygdala; Analysis of Variance; Animals; Calcium Channel Blockers; Catalase; Chronic Disease; Diseas | 2013 |
Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension.
Topics: Acute Disease; Administration, Topical; Animals; Axons; Chronic Disease; Disease Models, Animal; Ele | 2013 |
Effects of lamotrigine and topiramate on hippocampal neurogenesis in experimental temporal-lobe epilepsy.
Topics: Adult Stem Cells; Animals; Anticonvulsants; Cell Proliferation; Cell Survival; Chronic Disease; Dend | 2010 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Chronic interictal psychosis responsive to aripiprazole.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Chronic Disease; Clonazepam; Delusions; | 2004 |
The relevance of monitoring lamotrigine serum concentrations in chronic pain patients.
Topics: Administration, Oral; Adult; Analgesics; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Respo | 2006 |
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Resistanc | 2008 |
[The use of Lamiktal in treating epilepsy in children and adolescents].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chronic Disease; Drug Evaluation; Drug | 1994 |
Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes.
Topics: Acute Disease; Analgesics; Animals; Anticonvulsants; Chronic Disease; Diabetes Mellitus, Experimenta | 1995 |
Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome.
Topics: Chronic Disease; Clinical Trials as Topic; Epilepsy; Follow-Up Studies; gamma-Aminobutyric Acid; Hum | 1996 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
Lamotrigine in the treatment of chronic refractory neuropathic pain.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Drug Therapy, Combination; Female; Hum | 2000 |
Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Topics: Acetates; Adolescent; Adult; Age of Onset; Aged; Amines; Anticonvulsants; Chronic Disease; Cyclohexa | 2000 |
A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy.
Topics: Anticonvulsants; Chronic Disease; Drug Therapy, Combination; Electroencephalography; England; Epilep | 2001 |
Lamotrigine in the treatment of depersonalization disorder.
Topics: Adult; Chronic Disease; Depersonalization; Drug Therapy, Combination; Female; Humans; Lamotrigine; M | 2001 |
[Gabapentin in the treatment of chronic intractable pain].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non | 2002 |